Literature DB >> 7295324

Synergistic effect of 5-fluorouracil and N-(phosphonacetyl)-L-aspartate on cell growth and ribonucleic acid synthesis in human mammary carcinoma.

B Ardalan, R I Glazer, T W Kensler, H N Jayaram, T Van Pham, J S Macdonald, D A Cooney.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7295324     DOI： 10.1016/0006-2952(81)90221-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  6 in total

1.  Design, synthesis, and bioactivity of novel inhibitors of E. coli aspartate transcarbamoylase.

Authors:  Joby Eldo; Sabrina Heng; Evan R Kantrowitz
Journal:  Bioorg Med Chem Lett       Date:  2006-12-21       Impact factor: 2.823

2.  Biochemical mechanisms for the scheduled synergism of (alpha S, 5S)-2 amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid and 5-fluorouracil in P388 leukemia.

Authors:  B Ardalan; B Chandrasekaran; H J Hrishikeshavan
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

3.  Incorporation of pyrimidines and 5-fluoropyrimidines into normal tissues and an adenocarcinoma transplanted into the liver in rat.

Authors:  P I Christensson; C Erichsen; P E Jönsson; U Stenram
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

4.  A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.

Authors:  Robert P Whitehead; Jacqueline K Benedetti; James L Abbruzzese; Bach Ardalan; Stephen Williamson; Ellen R Gaynor; Stanley P Balcerzak; John S Macdonald
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

5.  Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.

Authors:  E Rosvold; R Schilder; J Walczak; S M DiFino; P J Flynn; T K Banerjee; W J Heim; P F Engstrom; R F Ozols; P J O'Dwyer
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study.

Authors:  Robert P Whitehead; Jacqueline K Benedetti; James L Abbruzzese; Bach Ardalan; J Wendall Goodwin; Stanley P Balcerzak; Wolfram E Samlowski; Heinz-Josef Lenz; John S Macdonald
Journal:  Invest New Drugs       Date:  2004-08       Impact factor: 3.850
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.